The role of splenectomy in the treatment of thrombocytopenic purpura due to systemic lupus erythematosus.
Splenectomy in the treatment of thrombocytopenic purpura associated with lupus erythematosus has afforded satisfactory overall results in a group of ten patients. Postoperative deaths occurred in two patients, each of whom had significant underlying problems. Clinical manifestations of SLE-induced thrombocytopenic purpura included ecchymoses, petechiae, menorrhagia, epistaxis, and hematuria. Splenectomy in this disorder should be reserved for cases in whom corticosteroids do not produce satisfactory results, or in whom unacceptably high doses are required. Follow-up indicates long term control of thrombocytopenic purpura following splenectomy.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004438:Ecchymosis / Q000209:etiology; D004844:Epistaxis / Q000209:etiology; D005260:Female; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008297:Male; D008595:Menorrhagia / Q000209:etiology; D008875:Middle Aged; D011183:Postoperative Complications; D011693:Purpura / Q000209:etiology; D011696:Purpura, Thrombocytopenic / Q000150:complications / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D013154:Spleen / Q000473:pathology; D013156:Splenectomy
D000305:Adrenal Cortex Hormones